EA202191354A1 - Способы и композиции для прогнозирования ответа на терапию воспалительного заболевания кишечника - Google Patents

Способы и композиции для прогнозирования ответа на терапию воспалительного заболевания кишечника

Info

Publication number
EA202191354A1
EA202191354A1 EA202191354A EA202191354A EA202191354A1 EA 202191354 A1 EA202191354 A1 EA 202191354A1 EA 202191354 A EA202191354 A EA 202191354A EA 202191354 A EA202191354 A EA 202191354A EA 202191354 A1 EA202191354 A1 EA 202191354A1
Authority
EA
Eurasian Patent Office
Prior art keywords
response
prediction
compositions
methods
disease therapy
Prior art date
Application number
EA202191354A
Other languages
English (en)
Inventor
Фредерик Барибо
Кэрри Бродмеркел
Силинь Ли
Такахиро Сато
Шэннон Телеско
Фэйфэй Ян
Прерак Десай
Original Assignee
Янссен Байотек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Байотек, Инк. filed Critical Янссен Байотек, Инк.
Publication of EA202191354A1 publication Critical patent/EA202191354A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Описаны биомаркеры, указывающие на ответ на терапию воспалительного заболевания кишечника, включая язвенный колит (ЯК) и болезнь Крона (CD). Также описаны зонды, способные обнаруживать биомаркеры, и связанные с ними способы и наборы для прогнозирования ответа на терапию воспалительного заболевания кишечника.
EA202191354A 2018-11-15 2019-11-14 Способы и композиции для прогнозирования ответа на терапию воспалительного заболевания кишечника EA202191354A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862767636P 2018-11-15 2018-11-15
PCT/US2019/061459 WO2020102519A1 (en) 2018-11-15 2019-11-14 Methods and compositions for prediction of response to a therapy of an inflammatory bowel disease

Publications (1)

Publication Number Publication Date
EA202191354A1 true EA202191354A1 (ru) 2021-08-11

Family

ID=70731162

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191354A EA202191354A1 (ru) 2018-11-15 2019-11-14 Способы и композиции для прогнозирования ответа на терапию воспалительного заболевания кишечника

Country Status (10)

Country Link
US (1) US20220002805A1 (ru)
EP (1) EP3880836A4 (ru)
JP (1) JP2022509061A (ru)
KR (1) KR20210091244A (ru)
CN (1) CN113316647A (ru)
AU (1) AU2019378008A1 (ru)
CA (1) CA3119294A1 (ru)
EA (1) EA202191354A1 (ru)
IL (1) IL283077A (ru)
WO (1) WO2020102519A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4015651A1 (en) * 2020-12-17 2022-06-22 Koninklijke Philips N.V. Treatment prediction and effectiveness of anti-tnf alpha treatment in ibd patients
WO2022140667A2 (en) * 2020-12-23 2022-06-30 Icahn School Of Medicine At Mount Sinai Method for treating crohn's disease
KR20230095769A (ko) 2021-12-22 2023-06-29 아주대학교산학협력단 Nampt 대사조절에 의한 염증성 장 질환 치료 또는 예방용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374927B2 (en) * 2004-05-03 2008-05-20 Affymetrix, Inc. Methods of analysis of degraded nucleic acid samples
US20070157325A1 (en) * 2005-12-30 2007-07-05 Shahriar Mojtahedian Process for identification of novel disease biomarkers in mouse models of alzheimer's disease including triple transgenic mice and products thereby
US7943310B2 (en) * 2006-08-30 2011-05-17 Centocor Ortho Biotech Inc. Methods for assessing response to therapy in subjects having ulcerative colitis
CA2734519C (en) * 2008-08-29 2018-11-13 Centocor Ortho Biotech Inc. Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel
WO2013087912A1 (en) * 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
WO2015094992A1 (en) * 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists
PL3380486T3 (pl) * 2015-11-24 2020-07-27 Theravance Biopharma R&D Ip, Llc Proleki związku będącego inhibitorem jak do leczenia choroby zapalnej układu żołądkowo-jelitowego
MX2019006823A (es) * 2016-12-14 2019-10-21 Progenity Inc Tratamiento de una enfermedad del tracto gastrointestinal con inhibidor de interleucina-12/interleucina-23 (il-12/il-23) liberado usando un dispositivo ingerible.

Also Published As

Publication number Publication date
EP3880836A4 (en) 2022-11-16
CN113316647A (zh) 2021-08-27
JP2022509061A (ja) 2022-01-20
EP3880836A1 (en) 2021-09-22
US20220002805A1 (en) 2022-01-06
WO2020102519A1 (en) 2020-05-22
KR20210091244A (ko) 2021-07-21
CA3119294A1 (en) 2020-05-22
AU2019378008A1 (en) 2021-06-03
IL283077A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
EA202191354A1 (ru) Способы и композиции для прогнозирования ответа на терапию воспалительного заболевания кишечника
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
BR112019004075A2 (pt) métodos para diagnosticar um indivíduo com suspeita de endometriose, para detectar mirna, para diagnosticar um indivíduo que apresenta sintomas de endometriose ou com suspeita de endometriose, para tratar um indivíduo com endometriose, para diagnosticar e tratar um indivíduo com suspeita de endometriose, para diagnosticar endometriose em um indivíduo, para diagnosticar ou prover um prognóstico para endometriose em um indivíduo e para monitorar uma resposta a um tratamento de endometriose em um indivíduo, e, kit.
MX352274B (es) Metodos para mejorar el diagnostico de enfermedad inflamatoria intestinal.
EA201791578A1 (ru) Панель биомаркеров для обнаружения рака
MY150234A (en) Predictive markers for ovarian cancer
MY191324A (en) Neutralizing anti-tl1a monoclonal antibodies
GB2503148A (en) Biomarker panels diagnostic methods and test kits for ovarian cancer
EA201790696A1 (ru) Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности
BR112018074853A2 (pt) métodos para detectar a presença de pelo menos um genogrupo de norovírus em uma amostra de fezes e para selecionar um paciente que sofre de gastroenterite aguda, e, kit
BR112016020053A2 (pt) métodos de previsão da reação de pacientes que sofrem de distúrbio inflamatório, de previsão da capacidade de reação de pacientes, de identificação de pacientes que sofrem de distúrbio inflamatório e de seu tratamento, usos de kit e kits
EA201390197A1 (ru) Применение hmgb1 в качестве биологического маркера воспалительных состояний кишечника, неинвазивный способ его определения в образцах фекалий и набор для этого
EA201792669A1 (ru) Igfbp3 и его применение
BR112018008799A2 (pt) método de prognóstico
NZ722492A (en) Specific biomarker set for non-invasive diagnosis of liver cancer
BR112016024480A2 (pt) seleção de célula mais rápida
MX2017006075A (es) Biomarcadores para la progresion de enfermedades en melanoma.
MX2017004516A (es) Métodos y sistemas para distinguir el síndrome del intestino irritable de la enfermedad inflamatoria intestinal y la enfermedad celíaca.
CA3056911A1 (en) Methods for diagnosing and treating inflammatory bowel disease
WO2015023503A3 (en) Compositions and methods for multimodal analysis of cmet nucleic acids
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
CL2023002393A1 (es) Anticuerpos anti-cd30l y usos de estos
WO2016198833A3 (en) Methods for analysing a urine sample
MX2023010694A (es) Métodos para predecir la respuesta al tratamiento en la colitis ulcerosa.